Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,599.00
Bid: 1,594.50
Ask: 1,595.50
Change: -19.00 (-1.17%)
Spread: 1.00 (0.063%)
Open: 1,608.00
High: 1,615.00
Low: 1,575.00
Prev. Close: 1,618.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

30 Oct 2020 17:08

RNS Number : 8332D
GlaxoSmithKline PLC
30 October 2020
 

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

GlaxoSmithKline PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Details of person subject to the notification obligation

Name

The Capital Group Companies, Inc.

City and country of registered office (if applicable)

Los Angeles, USA

4. Full name of shareholder(s)  (if different from 3)

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reached:

27/10/2020

6. Date on which issuer notified (DD/MM/YYYY):

29/10/2020

7. Total positions of person(s) subject to the notification obligation:

% of voting rights attached to shares

(total of 8.A)

% of voting rights through financial instruments

(total of 8.B.1 + 8.B.2)

Total of both in %

(8.A + 8.B)

Total number of voting rights of issuer

Resulting situation on the date on which threshold was crossed or reached

5.04%

0.00%

5.04%

5,017,375,238

Position of previous notification (if applicable)

4.99%

0.00%

4.99%

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached:

A: Voting rights attached to shares

Class/type of shares ISIN code (if possible)

Number of voting rights

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB0009252882 Common Stock

207,532,584

4.14%

US37733W1053 Depository Receipt

45,497,838

0.91%

SUBTOTAL 8.A

253,030,422

5.04%

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expiration date

Exercise/ Conversion Period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

N/A

SUBTOTAL 8.B.1

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expiration date

Exercise/ Conversion Period

Physical or cash settlement

Number of voting rights

% of voting rights

N/A

SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary)

X

Name

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Capital Research and Management Company

5.02%

5.02%

Capital Bank and Trust Company

Capital International, Inc.

Capital International Sàrl

Capital International Limited

Total

5.04%

5.04%

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional information:

 

The Capital Group Companies, Inc. ("CGC") is the parent company of Capital Research and Management Company ("CRMC") and Capital Bank & Trust Company ("CB&T"). CRMC is a U.S.-based investment management company that serves as investment manager to the American Funds family of mutual funds, other pooled investment vehicles, as well as individual and institutional clients. CRMC and its investment manager affiliates manage equity assets for various investment companies through three divisions, Capital Research Global Investors, Capital International Investors and Capital World Investors. CRMC is the parent company of Capital Group International, Inc. ("CGII"), which in turn is the parent company of four investment management companies ("CGII management companies"): Capital International, Inc., Capital International Limited, Capital International Sàrl and Capital International K.K. CGII management companies and CB&T primarily serve as investment managers to institutional and high net worth clients. CB&T is a U.S.-based investment management company that is a registered investment adviser and an affiliated federally chartered bank.

Neither CGC nor any of its affiliates own shares of the Issuer for its own account. Rather, the shares reported on this Notification are owned by accounts under the discretionary investment management of one or more of the investment management companies described above.

 

 

Place of completion

Los Angeles

Date of completion

29/10/2020

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLMMBRTMTMJBAM
Date   Source Headline
14th Feb 20237:00 amRNSDirector/PDMR Shareholding
13th Feb 20235:35 pmRNSEMTN Notes repurchase results
10th Feb 20233:30 pmRNSDirector/PDMR Shareholding
10th Feb 20237:05 amRNSJemperli full FDA approval following GARNET trial
10th Feb 20237:00 amRNSJemperli FDA ODAC positive outcome
2nd Feb 20237:00 amRNSDaprodustat approved by US FDA for anaemia of CKD
1st Feb 20233:30 pmRNSDirector/PDMR Shareholding
1st Feb 20233:00 pmRNSTotal Voting Rights
1st Feb 20237:05 amRNSBenlysta granted Orphan Drug Designation by US FDA
1st Feb 20237:00 amRNSFinal Results
18th Jan 20233:30 pmRNSDirector/PDMR Shareholding
17th Jan 20233:30 pmRNSDirector/PDMR Shareholding
16th Jan 20233:30 pmRNSDirector/PDMR Shareholding
13th Jan 20233:30 pmRNSDirector/PDMR Shareholding
12th Jan 20233:30 pmRNSDirector/PDMR Shareholding
3rd Jan 20233:00 pmRNSTotal Voting Rights
22nd Dec 20223:30 pmRNSDirector/PDMR Shareholding
21st Dec 20223:35 pmRNSDirector/PDMR Shareholding
21st Dec 20223:30 pmRNSDirector/PDMR Shareholding
15th Dec 20223:30 pmRNSBoard and Committee Changes
13th Dec 20223:30 pmRNSDirector/PDMR Shareholding
7th Dec 20227:00 amRNSStatement: Zantac (ranitidine) litigation
5th Dec 20224:00 pmRNSTransfer of Treasury Shares
2nd Dec 20223:30 pmRNSDirector/PDMR Shareholding
2nd Dec 20227:00 amRNSEMA file accepted for momelotinib
2nd Dec 20227:00 amRNSJemperli positive trial in endometrial cancer
1st Dec 20223:00 pmRNSTotal Voting Rights
25th Nov 20224:47 pmRNSPublication of Final Terms of EMTN Notes
24th Nov 20223:00 pmRNSGSK publishes provisional 2023 dividend dates
22nd Nov 20224:00 pmRNSPublication of Supplementary EMTN Prospectus
22nd Nov 20227:00 amRNSBlenrep US Update
21st Nov 20223:30 pmRNSDirector/PDMR Shareholding
18th Nov 20224:00 pmRNSPublication of EMTN Supplementary Prospectus
15th Nov 20224:00 pmRNSBlock listing Interim Review
15th Nov 20223:53 pmRNSFinal results of outstanding Notes Tender Offer
15th Nov 20227:00 amRNSInterim results of outstanding Notes Tender Offer
11th Nov 20227:00 amRNSGSK Update: Zejula 2L in US
10th Nov 20226:10 pmRNSSanofi-GSK COVID booster vaccine approved by EU
10th Nov 20223:30 pmRNSDirector/PDMR Shareholding
10th Nov 20229:00 amRNSBlock Listing Application
8th Nov 20229:26 amRNSLaunch of Tender Offer for outstanding Notes
7th Nov 20227:00 amRNSDREAMM-3 phase III trial for Blenrep
3rd Nov 20221:00 pmRNSPublication of Suppl.Prospcts
3rd Nov 20227:00 amRNSIDMC recommends gepotidacin early efficacy stop
2nd Nov 20227:01 amRNS3rd Quarter Results
2nd Nov 20227:00 amRNSGSK RSV vaccine: US FDA Priority Review
1st Nov 20223:00 pmRNSTotal Voting Rights
28th Oct 20227:00 amRNSEMA validates MAA for cabotegravir LA for PrEP
28th Oct 20227:00 amRNSEMA accepts GSK RSV older adult vaccine for review
27th Oct 20227:05 amRNSGSK announces FDA meeting outcome on daprodustat

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.